High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013
>Go!

Actavis Global Operations has more than 30 manufacturing facilities around the world. Capabilities include finished dosage form manufacturing as well as active pharmaceutical ingredient (API) development and manufacturing.

We also have biosimilars capabilities headquartered at our state-of-the-art biosimilar development center in Liverpool, U.K.

Map: Actavis supply chain, manufacturing sites